Onkologie. 2020:14(6):268-270 | DOI: 10.36290/xon.2020.091

Neoadjuvant therapy in rectal cancer

Monika Blažková
Interní hematologická a onkologická klinika, Brno

Colon and rectal cancers rank highest among adult tumors. Sixty percent of rectal tumors are stage 1, 2, and 3. Unfortunately, 40 % are diagnosed in clinical stage IV. The approach to the treatment of rectal cancer is multimodal. It involves a surgeon, endoscopist, radiation and clinical oncologist, and radiologist. It includes both systemic and local treatment, including radiotherapy. A neoadjuvant approach is used in stage T3 disease, especially in the presence of nodal involvement. The goals of neoadjuvant treatment are twofold: downstaging and reducing the risk of recurrence.

Keywords: neoadjuvancy, locally advanced rectal cancer, radiotherapy.

Published: January 8, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blažková M. Neoadjuvant therapy in rectal cancer. Onkologie. 2020;14(6):268-270. doi: 10.36290/xon.2020.091.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neoadjuvantní onkologická léčba karcinomu rekta - soubor Fakultní nemocnice v Motole >> Linkos.cz. Linkos: Česká onkologická společnost České lékařské společnosti J. E. Purkyně >> Linkos.cz [online]. Copyright © 2020 ČOS ČLS JEP [cit. 20.10.2020]. Dostupné z: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/kongresy/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/neoadjuvantni-onkologicka-lecba-karcinomu-rekta-soubor-fakultni-nemocnice-v-moto/.
    2. Petruželka L, et al. Kolorektální karcinom. Praha: Farmakon press, 2002: 73-85.
    3. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 J Clin Oncol. 2009; 27(31): 5124-30. doi: 10.1200/JCO.2009.22.0467. Epub 2009 Sep 21. Go to original source... Go to PubMed...
    4. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-up of 11 Years. J Clin Oncol 2012; 30: 1926-1933. Go to original source... Go to PubMed...
    5. Methy N. Surrogate end points for all survival and local control in neodjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial Annals of Oncoogy 2010; 21(3): P518-524.
    6. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin Ch, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B. Thierry Conroy Affiliations expand, Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer, PMID: 23109696, DOI: 10.1200/JCO.2012.42.8771. Go to original source... Go to PubMed...
    7. Aschele C, Lonardi S, Cionini L, Pinto C, Cordio SS, Rosati G. Final results of STAR-01: a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.
    8. Hofheinz. The Lancet Oncology, 2012; 13(6): 579-588. Go to original source... Go to PubMed...
    9. Šlampa P, et al. Radiační onkologie v praxi. Brno: MOÚ, 2011; 3563: 72-75.
    10. NCCN guidlines, Rectal cancer.
    11. SVOD Report. SVOD [online]. Dostupné z: https://svod.cz/report.php?diag=C18.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.